EA201791656A1 - Соединения 4-метилсульфонилзамещенной пиперидинмочевины для лечения дилатационной кардиомиопатии (dcm) - Google Patents

Соединения 4-метилсульфонилзамещенной пиперидинмочевины для лечения дилатационной кардиомиопатии (dcm)

Info

Publication number
EA201791656A1
EA201791656A1 EA201791656A EA201791656A EA201791656A1 EA 201791656 A1 EA201791656 A1 EA 201791656A1 EA 201791656 A EA201791656 A EA 201791656A EA 201791656 A EA201791656 A EA 201791656A EA 201791656 A1 EA201791656 A1 EA 201791656A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dcm
methylsulfonyl
treatment
dilated cardiomyopathy
substituted piperidine
Prior art date
Application number
EA201791656A
Other languages
English (en)
Other versions
EA036923B1 (ru
Inventor
Йохан Ослоб
Даниелль Обель
Дзае Ким
Роберт Макдауэлл
Юнхун Сун
Арвиндер Сран
Минь Чжун
Original Assignee
Миокардиа, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Миокардиа, Инк. filed Critical Миокардиа, Инк.
Publication of EA201791656A1 publication Critical patent/EA201791656A1/ru
Publication of EA036923B1 publication Critical patent/EA036923B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение предусматривает новые соединения 4-метилсульфонилзамещенной пиперидинмочевины, которые применимы для лечения дилатационной кардиомиопатии (DCM) и состояний, ассоциированных с лево- и/или правожелудочковой систолической дисфункцией или систолическим резервом. Описан синтез и характеристика соединений, а также способы лечения DCM и других форм заболеваний сердца.
EA201791656A 2015-01-22 2016-01-21 Соединения 4-метилсульфонилзамещенной пиперидинмочевины для лечения дилатационной кардиомиопатии (dcm) EA036923B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562106571P 2015-01-22 2015-01-22
PCT/US2016/014365 WO2016118774A1 (en) 2015-01-22 2016-01-21 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)

Publications (2)

Publication Number Publication Date
EA201791656A1 true EA201791656A1 (ru) 2017-11-30
EA036923B1 EA036923B1 (ru) 2021-01-15

Family

ID=55275230

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791656A EA036923B1 (ru) 2015-01-22 2016-01-21 Соединения 4-метилсульфонилзамещенной пиперидинмочевины для лечения дилатационной кардиомиопатии (dcm)

Country Status (35)

Country Link
US (1) US9925177B2 (ru)
EP (2) EP4234017A3 (ru)
JP (1) JP6712275B2 (ru)
KR (2) KR20230145504A (ru)
CN (3) CN111393414B (ru)
AU (3) AU2016209200B2 (ru)
BR (1) BR112017015627B1 (ru)
CA (1) CA2974370C (ru)
CL (1) CL2017001871A1 (ru)
CO (1) CO2017008398A2 (ru)
CR (1) CR20170370A (ru)
DK (1) DK3247707T3 (ru)
DO (2) DOP2017000166A (ru)
EA (1) EA036923B1 (ru)
EC (1) ECSP17054181A (ru)
ES (1) ES2953480T3 (ru)
FI (1) FI3247707T3 (ru)
GT (1) GT201700163A (ru)
HK (1) HK1246775A1 (ru)
HR (1) HRP20230737T1 (ru)
HU (1) HUE063410T2 (ru)
IL (5) IL295547A (ru)
LT (1) LT3247707T (ru)
MX (3) MX2021010778A (ru)
PE (2) PE20212253A1 (ru)
PH (1) PH12017501279A1 (ru)
PL (1) PL3247707T3 (ru)
PT (1) PT3247707T (ru)
RS (1) RS64432B1 (ru)
SG (2) SG11201705928XA (ru)
SI (1) SI3247707T1 (ru)
TN (1) TN2017000320A1 (ru)
UA (1) UA119905C2 (ru)
WO (1) WO2016118774A1 (ru)
ZA (1) ZA201704777B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10758525B2 (en) 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
CN111601798B (zh) 2017-09-13 2023-08-11 美国安进公司 双酰胺肌节活化化合物及其用途
BR112020014428A2 (pt) 2018-01-19 2020-12-01 Cytokinetics, Inc. composto, composição farmacêutica, e, métodos para o tratamento de uma doença cardíaca em um indivíduo, para o tratamento de uma doença ou condição que está associada com cavidade ventricular esquerda pequena e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia do miocárdio ou fibrose cardíaca, para o tratamento de uma doença ou condição selecionada dentre distrofias musculares e doenças de armazenamento do glicogênio e para inibição do sarcômero cardíaco
AU2019213854C1 (en) * 2018-02-01 2023-12-14 MyoKardia, Inc. Pyrazole compounds and preparation thereof
WO2020005887A1 (en) 2018-06-26 2020-01-02 Cytokinetics, Inc. Cardiac sarcomere inhibitors
GB201813312D0 (en) 2018-08-15 2018-09-26 Modern Biosciences Ltd Compounds and their therapeutic use
KR20210068422A (ko) 2018-08-31 2021-06-09 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
GB201905520D0 (en) 2019-04-18 2019-06-05 Modern Biosciences Ltd Compounds and their therapeutic use
BR112021023074A2 (pt) * 2019-05-19 2022-03-29 Myokardia Inc Tratamento de disfunção sistólica e insuficiência cardíaca com fração de ejeção reduzida com o composto (r)-4-(l-(1-((3-(difluorometil)-l--1-metil-1h-pirazol-4-il)sulfonil)-l-1-fluoroetil)-n-(isoxazol-3-il)piperidina-l-1-carboxamida
AU2020315605A1 (en) * 2019-07-16 2022-03-03 MyoKardia, Inc. Polymorphic forms of (R)-4-(1-((3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-(isoxazol-3-yl)piperidine-1-carboxamide
CN110407744A (zh) * 2019-08-13 2019-11-05 上海毕得医药科技有限公司 一种1-(4-氨基吡啶-2-基)乙酮的合成方法
KR20230024977A (ko) * 2020-06-15 2023-02-21 미요카디아, 인크. 심방 기능 부전의 치료
KR102541297B1 (ko) 2020-08-18 2023-06-09 가톨릭대학교 산학협력단 확장성 심근병 모델 및 이의 제조방법
WO2022187501A1 (en) 2021-03-04 2022-09-09 Cytokinetics, Inc. Cardiac sarcomere inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117882A2 (en) * 2004-04-20 2005-12-15 Incyte Corporation Hydroxamic acid derivatives as metalloprotease inhibitors
EP2862859B1 (en) * 2004-06-17 2018-07-25 Cytokinetics, Inc. Compounds, compositions and methods
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
US8324178B2 (en) * 2008-10-31 2012-12-04 The Regents Of The University Of California Method of treatment using alpha-1-adrenergic agonist compounds
WO2010068452A1 (en) * 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
US8933229B2 (en) * 2009-11-11 2015-01-13 Sumitomo Dainippon Pharma Co., Ltd. 8-azabicyclo[3.2.1]octane-8-carboxamide derivative

Also Published As

Publication number Publication date
BR112017015627A2 (pt) 2018-03-13
KR102585550B1 (ko) 2023-10-10
ES2953480T3 (es) 2023-11-13
IL295547A (en) 2022-10-01
US9925177B2 (en) 2018-03-27
LT3247707T (lt) 2023-08-25
CA2974370C (en) 2023-10-31
HRP20230737T1 (hr) 2023-10-13
PT3247707T (pt) 2023-08-31
CN118164961A (zh) 2024-06-11
CA2974370A1 (en) 2016-07-28
PL3247707T3 (pl) 2023-12-11
CN107428719B (zh) 2020-03-27
KR20230145504A (ko) 2023-10-17
KR20170113578A (ko) 2017-10-12
EP4234017A3 (en) 2023-10-18
CN107428719A (zh) 2017-12-01
MX2017009540A (es) 2017-10-20
US20160243100A1 (en) 2016-08-25
EP3247707A1 (en) 2017-11-29
MX2021010778A (es) 2022-08-11
NZ734020A (en) 2023-11-24
EP4234017A2 (en) 2023-08-30
ZA201704777B (en) 2023-07-26
AU2016209200A1 (en) 2017-08-10
AU2020244490B2 (en) 2022-12-01
CL2017001871A1 (es) 2018-04-13
JP2018502883A (ja) 2018-02-01
DOP2022000172A (es) 2022-09-30
MX2022007040A (es) 2022-06-24
IL253552B (en) 2019-12-31
IL271034A (en) 2020-01-30
IL279247A (en) 2021-01-31
CN111393414A (zh) 2020-07-10
TN2017000320A1 (en) 2019-01-16
JP6712275B2 (ja) 2020-06-17
HUE063410T2 (hu) 2024-01-28
CO2017008398A2 (es) 2017-10-31
EP3247707B1 (en) 2023-05-31
CN111393414B (zh) 2024-05-07
FI3247707T3 (fi) 2023-08-22
CR20170370A (es) 2017-10-20
BR112017015627B1 (pt) 2022-11-16
DK3247707T3 (da) 2023-07-03
PH12017501279A1 (en) 2018-01-29
ECSP17054181A (es) 2019-02-28
AU2020244490A1 (en) 2020-10-29
RS64432B1 (sr) 2023-09-29
DOP2017000166A (es) 2017-10-15
PE20171511A1 (es) 2017-10-20
HK1246775A1 (zh) 2018-09-14
PE20212253A1 (es) 2021-11-24
AU2016209200B2 (en) 2020-07-02
SG11201705928XA (en) 2017-08-30
AU2023200361A1 (en) 2023-02-23
IL286369A (en) 2021-10-31
WO2016118774A1 (en) 2016-07-28
SI3247707T1 (sl) 2023-10-30
EA036923B1 (ru) 2021-01-15
GT201700163A (es) 2018-10-18
IL253552A0 (en) 2017-09-28
SG10201913047UA (en) 2020-02-27
UA119905C2 (uk) 2019-08-27

Similar Documents

Publication Publication Date Title
EA201791656A1 (ru) Соединения 4-метилсульфонилзамещенной пиперидинмочевины для лечения дилатационной кардиомиопатии (dcm)
EA201690066A1 (ru) Соединения пиримидиндиона
EA201990912A1 (ru) Анти-lag-3 антитела и их композиции
CY1123988T1 (el) Ενωση πυριδινης
EA201791002A1 (ru) Новые соединения, модулирующие fxr (nr1h4)
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
EA202090720A1 (ru) ПРОИЗВОДНЫЕ GalNAc
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
EA201890442A1 (ru) Получение фоторецепторов для лечения заболеваний сетчатки
EA201790800A1 (ru) Замещенные производные бензотиофенила в качестве агонистов gpr40 для лечения диабета ii типа
EA201891342A1 (ru) Изоиндольные соединения
EA201992302A1 (ru) Соединения, используемые в качестве ингибиторов alcat1
EA201992233A1 (ru) Соединения изоксазолкарбоксамида и их применение
EA201992360A1 (ru) Кристаллические формы (s)-афоксоланера
EA201892698A1 (ru) Производные пиразолиламинобензимидазола в качестве ингибиторов jak
EA202190045A1 (ru) Составы/композиции, содержащие ибрутиниб
NZ772098A (en) 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
EA202090336A1 (ru) Соединения, их соли и способы лечения заболеваний
EA201692485A1 (ru) Новая полиморфная форма n-[2-(6-фтор-1h-индол-3-ил)этил]-3-(2,2,3,3-тетрафторпропокси)бензиламина гидрохлорида для лечения болезни альцгеймера
EA202092947A1 (ru) Анти-pvrig/анти-tigit биспецифические антитела и способы их применения
EA201991851A1 (ru) Антитела против sirp-альфа
EA201791389A1 (ru) Способы и композиции антител, направленных против bmp6
TH173740B (th) สไพโรไซโคลเฮพเทนเป็นสารยับยั้งของ rock

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM